The p.M292T NDUFS2 mutation causes complex I-deficient Leigh syndrome in multiple families by Tuppen, Helen A. L. et al.
BRAIN
A JOURNAL OF NEUROLOGY
The p.M292T NDUFS2 mutation causes complex
I-deﬁcient Leigh syndrome in multiple families
Helen A. L. Tuppen,
1 Vanessa E. Hogan,
1 Langping He,
1 Emma L. Blakely,
1 Lisa Worgan,
2
Mazhor Al-Dosary,
1 Gabriele Saretzki,
3 Charlotte L. Alston,
1 Andrew A. Morris,
4 Michael Clarke,
5
Simon Jones,
4 Anita M. Devlin,
6 Sahar Mansour,
7 Zoﬁa M. A. Chrzanowska-Lightowlers,
1
David R. Thorburn,
8 Robert McFarland
1,6 and Robert W. Taylor
1
1 Mitochondrial Research Group, Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
2 Department of Clinical Genetics, Liverpool Hospital, Liverpool, NSW 2170, Australia
3 Crucible Laboratory, Institute for Ageing and Health, International Centre for Life, Newcastle upon Tyne NE1 3BZ, UK
4 Willink Biochemical Genetics Unit, Manchester Children’s Hospital, Manchester M13 9WL, UK
5 Department of Paediatric Neurology, Leeds General Inﬁrmary, Leeds LS1 3EX, UK
6 Department of Paediatric Neurology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE4 6BE, UK
7 South West Thames Regional Genetics Unit, St George’s University of London, London SW17 0RE, UK
8 Mitochondrial and Metabolic Research Group, Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne,
Victoria 3052, Australia
Correspondence to: Robert W. Taylor,
Mitochondrial Research Group,
Institute for Ageing and Health,
Newcastle University,
Medical School,
Framlington Place,
Newcastle upon Tyne NE2 4HH, UK
E-mail: r.w.taylor@ncl.ac.uk
Isolated complex I deﬁciency is the most frequently observed oxidative phosphorylation defect in children with mitochondrial
disease, leading to a diverse range of clinical presentations, including Leigh syndrome. For most patients the genetic cause of
the biochemical defect remains unknown due to incomplete understanding of the complex I assembly process. Nonetheless, a
plethora of pathogenic mutations have been described to date in the seven mitochondrial-encoded subunits of complex I as well
as in 12 of the nuclear-encoded subunits and in six assembly factors. Whilst several mitochondrial DNA mutations are recurrent,
the majority of these mutations are reported in single families. We have sequenced core structural and functional
nuclear-encoded subunits of complex I in a cohort of 34 paediatric patients with isolated complex I deﬁciency, identifying
pathogenic mutations in 6 patients. These included a novel homozygous NDUFS1 mutation in an Asian child with Leigh
syndrome, a previously identiﬁed NDUFS8 mutation (c.236C4T, p.P79L) in a second Asian child with Leigh-like syndrome
and six novel, compound heterozygous NDUFS2 mutations in four white Caucasian patients with Leigh or Leigh-like syndrome.
Three of these children harboured an identical NDUFS2 mutation (c.875T4C, p.M292T), which was also identiﬁed in conjunction
with a novel NDUFS2 splice site mutation (c.866+4A4G) in a fourth Caucasian child who presented to a different diagnostic
centre, with microsatellite and single nucleotide polymorphism analyses indicating that this was due to an ancient common
founder event. Our results conﬁrm that NDUFS2 is a mutational hotspot in Caucasian children with isolated complex I deﬁciency
and recommend the routine diagnostic investigation of this gene in patients with Leigh or Leigh-like phenotypes.
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Introduction
Complex I [nicotinamide adenine dinucleotide (NADH)–ubiquinone
oxidoreductase] is the ﬁrst, largest ( 1MDa) and most intricate
multimeric component of the mitochondrial respiratory chain,
responsible for the transfer of electrons from NADH to ubiquinone
coupled with the translocation of protons across the inner mito-
chondrial membrane. The enzyme is L-shaped, with a hydrophilic
peripheral arm that protrudes into the mitochondrial matrix and a
hydrophobic arm nestled in the inner mitochondrial membrane.
Human complex I consists of 45 subunits, of which 14 highly
conserved subunits are thought to form the minimal functional
core of the complex (ND1-6, ND4L, NDUFS1-3, NDUFS7-8,
NDUFV1-2) (Walker, 1992; Carroll et al., 2006). Seven of the
complex I subunits are encoded by the mitochondrial genome
(ND1-6 and ND4L), whilst all other subunits and all accessory
factors necessary for the correct assembly of complex I are
encoded by nuclear genes.
Structural integrity is important for complex I functionality and,
given the enzyme’s structural complexity, it is not surprising
that isolated complex I deﬁciency is the most frequently observed
oxidative phosphorylation disorder in children with mitochondrial
disease (Kirby et al., 1999; Triepels et al., 2001). A wide variety
of clinical presentations are associated with isolated complex I deﬁ-
ciency, including hepatopathy, cardiomyopathy, fatal congenital
lactic acidosis and Leigh syndrome, where neurological fea-
tures such as central hypopnoea, dystonia, hypotonia, dysphagia
and myopathy are common (Distelmaier et al., 2009). Identifying
the plethora of mutations responsible for complex I deﬁciency is
challenging but essential for providing accurate and helpful
diagnostic counselling. Mitochondrial DNA (mtDNA) mutations,
found in all seven mtDNA genes (Kirby et al., 1999; Lebon
et al., 2003; McFarland et al., 2004), are thought to account
for  25% of cases (Lebon et al., 2003; Bugiani et al., 2004;
McFarland et al., 2004), suggesting that nuclear gene defects must
be responsible for the remainder of observed cases. To date,
pathogenic nuclear DNA mutations have been reported in 12 com-
plex I subunit genes, NDUFS1-4, NDUFS6-8, NDUFV1-2,
NDUFA1-2 and NDUFA11 (Loeffen et al., 1998a, 2001;
Schuelke et al., 1999; Triepels et al., 1999; Benit et al., 2001,
2003, 2004; Kirby et al., 2004; Fernandez-Moreira et al., 2007;
Berger et al., 2008; Hoefs et al., 2008), and six complex I assembly
factor genes, NDUFAF1, NDUFAF2, NDUFAF3, NDUFAF4, C8orf38
and C20orf7 (Ogilvie et al., 2005; Dunning et al., 2007; Pagliarini
et al., 2008; Saada et al., 2008, 2009; Sugiana et al., 2008; Gerards
et al., 2009).
Here, we describe the repeated ﬁnding of a heterozygous
NDUFS2 nuclear complex I gene mutation (c.875T4C,
p.M292T), which, in conjunction with secondary unique heterozy-
gous mutations in the same gene, causes isolated complex I deﬁ-
ciency in four unrelated white Caucasian patients.
Patients
A cohort of 34 paediatric patients with identiﬁed isolated complex
I deﬁciency in skeletal muscle was selected for this study (selected
patients are presented in Table 1). The cohort was clinically het-
erogeneous, presenting with a variety of phenotypes, including
Leigh syndrome, isolated hypertrophic cardiomyopathy and con-
genital lactic acidosis. In each case, sequencing of the entire mito-
chondrial genome had previously excluded the possibility of
mtDNA point mutations as the cause of the biochemical defect.
Written informed consent was obtained from all families in accord-
ance with the Declaration of Helsinki and the study was approved
by the local Ethics Committee.
Case reports
Patient 3
This female was the second child of non-consanguineous
Caucasian parents who have a healthy son. Her birth weight at
3.03kg was on the 25th centile, but she fed poorly and vomited
repeatedly, so that by 16 weeks her weight was on the 2nd
centile. She presented at 8 months with failure to thrive, vomiting
and developmental delay. Examination revealed ﬁne sparse hair,
generalized hypotonia and intermittent bilateral pendular nystag-
mus. Plasma and CSF lactate were elevated at 11.66 and
5.56mmol/l, respectively, and cranial MRI scan demonstrated
symmetrical abnormal signal in the cerebral peduncles, dorsal
pons and upper medulla, with a lactate peak clearly visible on
magnetic resonance spectroscopy. Nasogastric tube feeding was
commenced, but episodes of vomiting continued regularly and
were often accompanied by a severe acidosis, encephalopathy
Table 1 Mitochondrial respiratory chain complex I
activities in patient skeletal muscle homogenates
Patient Mutated gene Muscle homogenate
Complex I
a Complex I/
Complex II
b
3 NDUFS2 0.021 (20%) 0.313
5 NDUFS1 0.024 (23%) 0.273
19 NDUFS2 0.028 (27%) 0.389
22 NDUFS2 0.014 (13%) 0.130
27 NDUFS2 0.017 (16%) 0.155
The activity of complex I in skeletal muscle from Patient 34 was assessed in a
separate diagnostic centre. It was shown to be 30% of control values. Complex I is
expressed as nanomoles NADH oxidized/min/unit citrate synthase. Complex II is
calculated as nanomoles 2,6-dichlorophenolindophenol reduced/min/unit citrate
synthase. Figures in brackets represent the percentage residual complex I activity
expressed in muscle.
a Control range (n=25): 0.104 0.036.
b Control range (n=25): 0.52–0.95.
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tient developed central hypopnoea and died.
Patient 5
This full-term female infant presented at age 4 months with axial
hypotonia, poor feeding, vomiting and failure to thrive. She subse-
quently developed intermittent nystagmus and would take up ﬁx-
ation only brieﬂy. Fundoscopy showed no abnormalities, and tone in
herlimbswasnormal,asweretendonreﬂexes.Headgrowthfellfrom
25thto0.4thcentileandcranialMRI(at8months)showedextensive
symmetrical abnormalities in the cerebral peduncles, anterior pons,
posterior limbs of the internal capsules and extensive T2 signal
change in the white matter of the cerebellar hemispheres. She then
developed spasticity in her limbs with brisk tendon reﬂexes.
Echocardiography was normal. The patient’s feeding was further
complicated by dysphagia, and nasogastric tube feeding was
initiated.At10.5monthsafurthersuddendeteriorationledtocentral
hypopnoea, limb hypotonia, encephalopathy and death 24h later.
The blood and CSF lactate concentrations were raised at 3.3 and
4.7mmol/l, respectively. Pyruvate dehydrogenase activity in cul-
tured ﬁbroblasts was normal.
The patient’s parents are ﬁrst cousins and they have a healthy
older son. Unfortunately, their second daughter was also affected
(Fig. 1A). Again, she was born at term and appeared normal for
the ﬁrst 2 months. Thereafter, her feeding deteriorated and she
developed truncal hypotonia and increasing irritability.
Subsequently, she also showed poor head growth, and visual ﬁx-
ation ceased at  6 months. At 7 months, she developed limb
hypertonia. She was managed with nasogastric tube feeding and
baclofen but continued to deteriorate and died aged 10 months.
Patient 19
This female is the youngest of six children and the only child of
the current non-consanguineous relationship. With the exception
of a half-brother with attention deﬁcit disorder, the other siblings
are healthy, as are both parents. She was born by breech delivery
at full term, but did not require resuscitation. She was initially slow
to feed, and gross motor skills were delayed due to four-limb dys-
tonia. She did not walk independently until 3 years and remains
unsteady at 9 years. Speech has also been delayed and further ham-
pered by a severe dysarthria secondary to dystonia of her face and
neck muscles, but communication is facilitated by the use of a com-
puterized communication device. Since the age of 6 years she has
had a number of seizures, although her EEG remains normal. Cranial
MRI revealed bilateral symmetrical increased T2 signal in the basal
ganglia. At the age of 9 years, she attends mainstream school and is
independently mobile, albeit with frequent falls.
Patient 22
This female is the only child of healthy non-consanguineous par-
ents. Psychomotor delay, learning difﬁculties and episodes of tonic
upward eye deviation were noted from infancy. She developed
progressive dystonia affecting all four limbs, optic nerve hypopla-
sia, dysarthria and dysphagia, requiring a gastrostomy at the age
of 11 years. Cranial MRI at 18 months demonstrated bilateral
low-density lesions in the cerebral peduncles with high T2 signal
in the thalami and frontal lobes. These changes resolved by
5 years, but new symmetrical lesions in the heads of the caudate
and lentiform nuclei were observed bilaterally and persisted when
the scan was repeated at 7.5 years. Blood and CSF lactate con-
centrations were normal, as was plasma biotinidase activity, but
activity of the pyruvate dehydrogenase complex in ﬁbroblasts was
slightly decreased. Immunostaining for the E1alpha subunit
showed no evidence of mosaicism.
Patient 27
This female was the second child of healthy non-consanguineous
parents; her brother is in good health. Born by elective Caesarean
section at 36 weeks gestation, weighing 1.49kg, she required no
resuscitation at birth, but 2h later was unwell with an elevated
plasma lactate of 18mmol/l. Plasma ammonia and glucose con-
centrations were normal, but urinary excretion of malate, fumarate
Figure 1 NDUFS8 homozygous mutation, c.236C4T (p.P79L). (A) Family 34 pedigree, (B) sequence electropherograms of NDUFS8 gene
with c.236 position highlighted in patient and family members and (C) amino acid alignment of NDUFS8 orthologues. Alignments were
generated with ClustalW using GenBank sequences from Mus musculus (NP_659119.2), Rattus norvegicus (NP_001099792.1), Homo
sapiens (NP_002487.1), Pan troglodytes (NP_001065248), Canis lupus familiaris (XP_852209.1), Bos taurus (NP_777243.2), Danio rerio
(NP_998304.1), Drosophila melanogaster (NP_524719.1), Arabidopsis thaliana (NP_178022.1), Oryza sativa (NP_001051420.1) and
Caenorhabditis elegans (NP_498595.1). Position p.79 (Homo sapiens) is indicated. Conserved sites are shown (asterisk).
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A mild metabolic acidosis persisted (plasma lactate 6–9mmol/l)
despite treatment with sodium bicarbonate. Swallowing subse-
quently deteriorated and feeding was further compromised
by gastro-oesophageal reﬂux and vomiting. Cranial MRI was
normal. Echocardiography demonstrated mild left ventricular
hypertrophy. At 3.5months of age, she had a respiratory arrest
and died. Pyruvate dehydrogenase complex activity in ﬁbroblasts
was decreased, but genetic investigations proved normal.
Mitochondrial respiratory chain analysis of a skeletal muscle
biopsy demonstrated an isolated deﬁciency of complex I.
Patient 34
This female was the second child of healthy consanguineous
Pakistani parents who have two other healthy daughters. Born
at 38 weeks gestation, she weighed 2.5kg on the 9th centile
and at 4 weeks she remained jaundiced with poor weight gain.
She was admitted to hospital for artiﬁcial ventilation following
an aspiration event that resulted in a respiratory arrest.
Hyperkalaemia with persistent acidosis and raised serum
(7.4mmol/l) and CSF lactate (5.5mmol/l) were noted.
Swallowing remained unsafe and she failed to thrive despite naso-
gastric tube feeds. The development of seizures prompted an EEG,
which demonstrated a diffusely slow record with occasional spikes.
She was subsequently readmitted to hospital on several occasions,
with hypoventilation and apnoea, and died following a respiratory
arrest at the age of 3 months. Extensive investigations including
biotinidase, acylcarnitine proﬁle and amino acids were normal in
blood. Urinary organic acids and activity of pyruvate dehydrogen-
ase in ﬁbroblasts were also normal, but mitochondrial respiratory
chain analysis of skeletal muscle revealed an isolated complex I
deﬁciency (30% of control values).
Patient 35
This male is described elsewhere (Patient 17 in Salemi R et al.,
submitted for publication). He presented at 34 months of age with
developmental delay, ataxia, nystagmus, optic atrophy and a mild,
persistent metabolic acidosis. Plasma lactate level was 3.2mmol/l
and CSF lactate was 2.7mmol/l. Urinary organic acids plus plasma
and urinary amino acids were all normal. CT brain scan without
contrast was normal at 6 years of age.
Materials and methods
Respiratory chain biochemistry
The activities of the respiratory chain complexes I–IV and the matrix
marker citrate synthase were determined in frozen skeletal muscle
homogenates from all 34 patients as previously described (Kirby
et al., 2007).
DNA extraction and whole genome
ampliﬁcation
Total genomic DNA was extracted from either muscle or blood
samples of 34 paediatric patients using the Qiagen DNA mini kit
(Qiagen, Crawley, UK) or Nucleon BACC3 Blood and Cell Culture
DNA kit (Tepnel, Manchester, UK), respectively.
Whole genome ampliﬁcation
Prior to polymerase chain reaction (PCR) ampliﬁcation of nuclear tar-
gets, whole genomes were ampliﬁed by multiple displacement ampli-
ﬁcation using 29 polymerase (REPLI-g Mini kit; Qiagen), as per the
manufacturer’s instructions.
Polymerase chain reaction ampliﬁcation
The entire mitochondrial genome was ampliﬁed using 36 sets of over-
lapping M13-tailed primers (Supplementary Tables 1 and 2). The
coding regions of nine nuclear encoded complex I genes
(NDUFS1-4, NDUFS7, NDUFS8, NDUFV1, NDUFV2 and NDUFAB1)
were ampliﬁed using intronic M13-tailed primers, designed to ﬂank the
coding sequences of the genes (Hinttala et al., 2005) (Supplementary
Table 3). All PCRs were carried out in 25ml volumes containing 0.65U
AmpliTaq Gold polymerase (Applied Biosystems, Warrington, UK),
1  AmpliTaq Gold buffer, 0.8mM of each primer, 100mM deoxynu-
cleoside triphosphates and 30-100ng DNA (mtDNA PCR) or 1ml
of ampliﬁed DNA (nuclear gene PCR). Where appropriate,
reactions were supplemented with 2% dimethyl sulphoxide
(Supplementary Table 3).
Sequencing
All PCR products were puriﬁed (ExoSapIT, GE Healthcare,
Buckinghamshire, UK) and sequenced with BigDye Terminator cycle
sequencing chemistries (Applied Biosystems) on an Applied
Biosystems ABI3100 Genetic Analyser. Sequence data were analysed
using SeqScape software (v2.1.1, Applied Biosystems) and compared
with the GenBank reference sequences: NC_012920 (revised
Cambridge reference sequence for human mtDNA), NM_005006.5
(NDUFS1), NM_004550.3 (NDUFS2), NM_004551.1 (NDUFS3),
NM_002495.1 (NDUFS4), NM_024407.3 (NDUFS7), NM_002496.1
(NDUFS8), NM_007103.2 (NDUFV1), NM_021074.2 (NDUFV2) and
NM_004994.1 (NDUFAB1).
Nuclear haplotype analysis
Patients 3, 19, 22 and 35 and their parents were genotyped for the
microsatellite markers D1S2635, D1S2707, D1S2771, D1S2705,
D1S2675, D1S2844 and D1S1677 and the single nucleotide poly-
morphisms (SNPs) rs686015, rs10594, rs11582932, rs1041068,
rs12402879, rs352685, rs512645, rs836, rs11576830, rs3924264,
rs2501875, rs3935401, rs382627, rs2007773, rs6683580,
rs12407444, rs2341481, rs4657136, rs1932933 and rs2341744.
SNPs with a minor allele frequency of 0.15–0.48 and located at
 100kb intervals up- and downstream of NDUFS2 were chosen.
Primer sequences for the microsatellite markers and map positions
were obtained from the UniSTS database of the National Center for
Biotechnology Information (Supplementary Table 4); primer sequences
for the SNPs were designed using Primer3 software (v0.4.0.) (Rozen
and Skaletsky, 2000) (Supplementary Table 5). Forward primers for
the microsatellite markers were 50-6-FAM-labelled; forward and re-
verse primers for the SNP analysis were M13-tailed. Reactions were
carried out in 25ml volumes containing 1U GoTaq polymerase
(Promega, Southampton, UK), 1  GoTaq buffer, 0.2mM of each
primer, 100mM deoxynucleoside triphosphates and 20–100ng DNA.
PCR products (1ml) were electrophoresed on an ABI3130xl Genetic
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ard (Applied Biosystems). Data were analysed using GeneMapper v4.0
software (Applied Biosystems).
Polymerase chain reaction/restriction
fragment length polymorphism analysis
The NDUFS1 c.1222C4T mutation was conﬁrmed by PCR/restriction
fragment length polymorphism (RFLP) analysis. The assay was per-
formed as previously described (Taylor et al., 2003) with modiﬁca-
tions. A 218-base pair fragment encompassing the mutation
site was ampliﬁed using the M13-tailed forward primer 50-TGTA
AAACGACGGCCAGTCATGGATTCTCTGTATGTCTTAAT-30 and re-
verse primer 50-ACCAACCTCTTTCGAATTCTAGC-30. PCR ampliﬁca-
tions were performed with an annealing temperature of 59 C and
PCR products were digested with 10U NlaIII (New England Biolabs,
Hitchin, UK). Wild-type amplicons contain a single NlaIII recognition
site and on digestion two fragments of 25 and 193bp are generated.
The c.1222C4T mutation creates an additional NlaIII site, and ampli-
cons harbouring this mutation are digested into three fragments of 25,
45 and 148bp.
Cell culture
Cultured skin ﬁbroblasts from Patients 3, 5, 19, 22 and 27 and from
two normal, paediatric controls were cultured as previously described
(Taylor et al., 2003).
RNA extraction and reverse transcription
Total RNA was extracted from ﬁbroblasts using Trizol (Invitrogen,
Paisley, UK) according to the manufacturer’s instructions. Reverse
transcription of the messenger RNA was performed using the
Superscript II reverse transcriptase kit (Invitrogen).
Measurement of reactive oxygen
species levels and mitochondrial mass
Reactive oxygen species levels in cultured skin ﬁbroblasts from Patients
3, 5, 19, 22 and 27 were measured as described previously (Saretzki
et al., 2008). Brieﬂy, cells (2 10
5) were stained at 37 C in serum-free
Dulbecco’s modiﬁed Eagle’s medium (Gibco, Paisley, UK) with 5mM
MitoSOX (Molecular Probes, Eugene, OR, USA) for 15min to measure
mitochondrial superoxide levels or with 10mM of nonyl acridine
orange (Molecular Probes) for 10min to ascertain mitochondrial
mass. Cells were analysed in a ﬂow cytometer (Partec, Mu ¨nster,
Germany) using blue excitation and the green (FL1) and red (FL3)
emission channels. System alignment and gain settings were adjusted
using ﬂuorescent beads. Cells were gated in forward scatter/side scat-
ter, and the median of the gated ﬂuorescence peak was used. Data
were corrected by subtraction of autoﬂuorescence levels in unstained
cells. Neonatal human skin ﬁbroblasts (Control 1), MRC-5 lung ﬁbro-
blasts (Control 3, both from the American Type Tissue Collection,
Rockville, Maryland, USA) and paediatric skin ﬁbroblasts from a
healthy child (Control 2) were used as controls. To determine statistical
signiﬁcance, two-sample unpaired Student t-tests between each pa-
tient and control sample were performed. A Bonferroni corrected
P-value 0.05 was considered statistically signiﬁcant.
Blue-native polyacrylamide gel
electrophoresis
Mitochondria-enriched fractions were prepared from 80% conﬂuent
225cm
2 ﬂasks of patient and control ﬁbroblasts and processed as
described elsewhere (Nijtmans et al., 2002). Sample protein concen-
trations were determined by Bradford assay. Protein samples
(75mg/lane) were separated on 4–13% blue-native gradient gels,
cast and run as previously described (Nijtmans et al., 2002). To
assess complex I assembly, electrophoresed native gels were incubated
for 1h with dissociating reagent (1% sodium dodecyl suphate, 1%
b-mercaptoethanol) prior to protein transfer onto polyvinylidene ﬂuor-
ide membranes (Immobilon-P, Millipore Corporation, Watford, UK).
Immunodetection was performed using primary monoclonal antibodies
raised against the complex I NDUFA9 and complex II 70kDa subunits
(MitoSciences, Cambridge BioScience, Cambridge, UK). ECL Plus
TM
(GE Healthcare Life Sciences, Buckinghamshire, UK) chemilumines-
cence was detected on a Storm 480 PhosphorImager (Molecular
Dynamics, Sunnyvale, California, USA). To determine in-gel complex
I activity, assays of NADH dehydrogenase activity were performed
in-gel with NADH and nitrotetrazolium blue (Sigma, Poole, UK) as
substrates, as previously described (Calvaruso et al., 2008).
Sodium dodecyl sulphate
polyacrylamide gel electrophoresis
Cell lysates were prepared from 80% conﬂuent 75cm
2 ﬂasks of pa-
tient and control ﬁbroblasts in 200ml lysis buffer (42.5mM Tris–HCl
pH 7.5, 127.5mM NaCl, 1.7mM MgCl2, 1% Nonidet P-40 and Roche
ethylenediaminetetraacetic acid protease inhibitor cocktail). Samples
were vortexed brieﬂy, spun at 560g for 2min at 4 C and the super-
natants retained. Protein concentrations were determined by Bradford
assay. Equal amounts of protein (10–15mg) were loaded and resolved
on 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis
(PAGE) gels. Following wet transfer onto polyvinylidene ﬂuoride mem-
branes western blotting was performed using monoclonal antibodies
against complex I NDUFS9, NDUFS3 and NDUFB8 and complex II
70kDa subunits (MitoSciences). A monoclonal antibody raised against
b-actin, clone AC-15, was also used (Sigma). ECL Plus (GE Healthcare
Life Sciences) chemiluminescence was detected on a Storm 480
PhosphorImager (Molecular Dynamics).
Results
Sequence variations in nuclear-encoded
complex I subunits
Nine nuclear-encoded complex I subunits (NDUFS1, NDUFS2,
NDUFS3, NDUFS4, NDUFS7, NDUFS8, NDUFV1, NDUFV2 and
NDUFAB1) were sequenced in a cohort of 34 paediatric patients
with demonstrated isolated complex I deﬁciency in skeletal muscle.
Twenty-four sequence variants were identiﬁed, almost half of
which are synonymous substitutions (Table 2). Of the remaining
13 non-synonymous substitutions, 4 are described SNPs (NDUFS2
p.P20T and p.P352A, NDUFS7 p.P23L and NDUFV2 p.V29A),
whilst the homozygous NDUFS8 sequence change in Patient 34
(p.P79L; Fig. 1) has been previously described by Loeffen et al.
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pathogenesis of a patient with Leigh-like syndrome. The ﬁnal
8 sequence changes are, to our knowledge, reported here for
the ﬁrst time. One homozygous NDUFS1 sequence variant,
c.1222C4T (predicting p.R408C), was identiﬁed in Patient 5
(Fig. 2). Two heterozygous NDUFS2 sequence variants were
discovered in Patient 27, c.413G4A (p.R138Q) and c.998G4A
(p.R333Q) (Fig. 3A), and a single heterozygous NDUFS2 substi-
tution, c.422A4G (p.Y141C), was detected in Patient 16. Patients
3, 19 and 22 all had an identical NDUFS2 transition, c.875T4C
(p.M292T), in addition to secondary unique heterozygous
sequence variants in the same gene, namely c.353G4A
(p.R118Q), c.1328T4A (p.M443K) and c.442G4A (p.E148K), re-
spectively (Fig. 3A). Interestingly, sequencing of a separate cohort
of patients with isolated complex I deﬁciency (n=34) in a diag-
nostic centre in Melbourne (Australia) also identiﬁed the NDUFS2
c.875T4C transition in a white Caucasian patient (Patient 35), in
conjunction with a second unique heterozygous substitution,
c.866+4A4G, located within the 50-splice site of intron 6. DNA
from this patient was included in the haplotype studies described
below.
Sequence variants NDUFS1 c.1222C4T and NDUFS2 c.353G4A,
c.413G4A, c.442G4A, c.875T4C, c.998G4A and c.1328T4A were
selected for further investigation. To exclude the possibility of
‘allele dropout’, the homozygous NDUFS1 c.1222C4T transition
was veriﬁed by PCR/RFLP (Fig. 2C). All seven substitutions
occur at highly evolutionarily conserved sites (Figs 2D and 3B)
and neither the NDUFS1 sequence variant nor the NDUFS2 sub-
stitutions were identiﬁed in panels of 120 and 380, respectively,
healthy, ethnically matched control chromosomes (data not
shown).
Further characterization of the NDUFS2 c.422A4G mutation
in Patient 16 was not performed due to a lack of observation
of disease in either parent and the absence of an additional po-
tentially pathogenic heterozygous change within NDUFS2 or any
of the other investigated genes. Following conﬁrmation of the
recessive inheritance of the NDUFS8 mutation in Patient 34 and
in view of the highly conserved nature of the affected residue
(Fig. 1B and C), no further investigations were carried out on
this patient, as the pathogenicity of this mutation has previously
been proven (Loeffen et al., 1998a; Ahlers et al., 2000; Ugalde
et al., 2004a).
Table 2 Nuclear complex I gene sequence variants
Gene Sequence
variant
refSNP ID Amino acid
change
Patients
Homozygous Heterozygous
Synonymous sequence variants
NDUFAB1 c.102C4T 31
c.108C4G rs466719 10
NDUFS1 c.414T4C rs11548670 1, 17
c.966G4T rs11548668 1, 4, 9, 10, 15, 17, 22, 24, 25, 30 3, 5, 7, 12, 13, 16, 23, 26, 31, 32, 33
c.1251A4G rs4147719 15, 22, 25, 30 1, 3, 4, 5, 9, 12, 13, 16, 17, 18, 23,
24, 26, 31, 32, 34
c.1371G4A 25
NDUFS2 c.1289C4T rs1136207 3, 13, 16, 19, 22, 27, 28, 29
NDUFS4 c.12G4C rs2279516 6, 8, 9, 12, 14, 21, 23, 26, 27 1, 2, 3, 4, 5, 7, 10, 16, 17, 18, 20,
22, 24, 25, 28, 29, 31, 32, 33, 34
c.198A4C rs31304 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 22, 23, 24, 25, 26,
27, 28, 29, 30, 31, 32, 33, 34
c.312A4G rs31303 2, 6, 8, 9, 10, 12, 13, 14, 22, 23,
24, 26, 27, 28, 29, 31
1, 3, 4, 5, 7, 11, 15, 16, 17, 25, 32,
33, 34
NDUFV2 c.201A4T rs41274300 3, 8, 15, 22 4, 7, 9, 12, 13, 24
Non-synonymous sequence variants
NDUFS1 c.1222C`T p.R408C 5
NDUFS2 c.58C4A rs11538340 p.P20T 1, 2, 29, 34
c.353G`A p.R118Q 3
c.413G`A p.R138Q 27
c.422A4G p.Y141C 16
c.442G`A p.E148K 22
c.875T`C p.M292T 3, 19, 22
c.998G`A p.R333Q 27
c.1054C4G rs11576415 p.P352A 20 6, 7, 11, 16, 27
c.1328T`A p.M443K 19
NDUFS7 c.68C4T rs1142530 p.P23L 3, 4, 5, 8, 9, 12, 16, 27, 29, 33 2, 6, 7, 13, 17, 23, 25, 34
NDUFS8 c.236C`T rs28939679 p.P79L 34
NDUFV2 c.86T4C rs906807 p.V29A 1, 3, 5, 6, 7, 9, 10, 12, 15, 16,
17, 18, 19, 20, 21, 22, 24, 25,
26, 27, 28, 29, 30, 31, 32, 33
2, 4, 11, 13, 14, 23, 34
Sequence variants selected for further investigation and the previously reported pathogenic NDUFS8 mutation (p.P79L) are highlighted in bold.
NDUFS2 mutations in Leigh syndrome Brain 2010: 133; 2952–2963 | 2957Figure 3 NDUFS2 heterozygous mutations, c.353G4A (p.R118Q), c.413G4A (p.R138Q), c.442G4A (p.E148K), c.875T4C (p.M292T),
c.998G4A (p.R333Q) and c.1328T4A (p.M443K). (A) Sequence electropherograms of NDUFS2 gene with c.353, c.413, c.442, c.875,
c.998 and c.1328 positions highlighted in Patients (P) 3, 19, 22 and 27; (B) amino acid alignments of NDUFS2 orthologues. Alignments
were generated with ClustalW using GenBank sequences from Mus musculus (NP_694704.1), Rattus norvegicus (NP_001011907.1),
Homo sapiens (NP_004541.1), Pan troglodytes (XP_001173728.1), Canis lupus familiaris (XP_536138.2), Bos taurus (NP_001068605.1),
Danio rerio (NP_001018481.1), Drosophila melanogaster (NP_651926.1), Arabidopsis thaliana (NP_085511.1), Oryza sativa
(YP_514643.1) and Caenorhabditis elegans (NP_498423.1). Positions p.118, p.138, p.148, p.292, p.333 and p.443
(Homo sapiens) are indicated. Conserved sites are indicated (asterisk).
Figure 2 NDUFS1 homozygous mutation, c.1222C4T (p.R408C). (A) Family 5 pedigree, (B) sequence electropherograms of NDUFS1
gene with c.1222 position highlighted in patient and family members, (C) conﬁrmation of homozygous c.1222C4T mutation by PCR–
RFLP. U=uncut; C1=Control 1; C2=Control 2. RFLP products were separated through a 12% non-denaturing polyacrylamide gel. The
wild-type PCR product contains a single NlaIII site, which cuts the 218-bp amplicon into two fragments of 193 and 25bp. In amplicons
harbouring the c.1222C4T mutation, a second NlaIII site is created that cuts the 193-bp fragment into two smaller fragments of 148 and
45bp. Fragment sizes (bp) are shown on the left; (D) amino acid alignment of NDUFS1 orthologues. Alignments were generated with
ClustalW using GenBank sequences from Mus musculus (NP_663493.1), Rattus norvegicus (NP_001005550.1), Homo sapiens
(NP_004997.4), Pan troglodytes (XP_516047.2), Canis lupus familiaris (XP_859697.1), Bos taurus (NP_777245.1), Danio rerio
(NP_001007766.1), Drosophila melanogaster (NP_727255.1), Arabidopsis thaliana (NP_568550.1), Oryza sativa (NP_001051072.1)
and Caenorhabditis elegans (NP_503733.1). Position p.408 (Homo sapiens) is indicated. Conserved sites are indicated (asterisk).
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alleles
Parental genomic DNA samples were sequenced to conﬁrm reces-
sive inheritance of the NDUFS1 and NDUFS2 alleles. Both
the mother and father of Patient 5 were revealed to be carriers
of the NDUFS1 c.1222C4T transition (Fig. 2B and C).
Unfortunately, DNA was unavailable from her unaffected brother;
however, her clinically affected sister was similarly homozygous for
this sequence variant. For all ﬁve NDUFS2 patients, each parent
was shown to be heterozygous for only one of the two substitu-
tions identiﬁed in respective patients (data not shown). During our
investigations, the mother of Patient 3 conceived a third preg-
nancy and the parents requested prenatal genetic testing.
Analysis of a chorionic villus biopsy failed to identify either of
the familial NDUFS2 mutations (c.353G4A or c.875T4C).
Nuclear and mitochondrial DNA
haplotype analysis
To determine whether the repeatedly observed NDUFS2
c.875T4C transition could be attributed to a common founder
event, Patients 3, 19, 22 and 35 and their parents were initially
genotyped for microsatellite markers located upstream (D1S2635,
D1S2707, D1S2771 and D1S2705) and downstream (D1S2675,
D1S2844 and D1S1677) of NDUFS2 (Supplementary Table 4).
D1S2705 was the only common ﬂanking marker in all four pa-
tients. Due to the shortfall of microsatellite markers within the
genomic region surrounding the NDUFS2 gene, a more exhaustive
investigation was subsequently carried out by SNP analysis, using
SNPs spaced  100kb apart upstream (rs686015, rs10594,
rs11582932, rs1041068, rs12402879, rs352685, rs512645, rs836
and rs11576830) and downstream (rs2501875, rs3935401,
rs382627, rs2007773, rs6683580, rs12407444, rs2341481,
rs4657136, rs1932933 and rs2341744) of NDUFS2. The intragenic
NDUFS2 SNPs, rs3924264 and rs1136207, were also assessed
(Supplementary Table 5). Up to 12 SNPs, spanning a region
 480-kb upstream and  520-kb downstream of NDUFS2, ap-
peared to co-segregate with the c.875C4T sequence variant in
all four patients, suggesting a mutation-speciﬁc haplotype
[rs352685 (G), rs512645 (A), D1S2705 (156), rs836 (G),
rs11576830 (C), rs3924264 (A), rs1136207 (T), rs2501875 (G),
rs3935401 (T), rs382627 (C/T), rs2007773 (A), rs6683580 (A)
and rs12407444 (A); Supplementary Fig. 1].
Mitochondrial DNA haplotypes were determined for each
c.875T4C patient from mtDNA polymorphisms. All patients be-
longed to independent Caucasian mitochondrial haplogroups,
namely V (Patient 3), K (Patient 19), J (Patient 22) and U
(Patient 35).
Fibroblast complex I activity
Investigation of complex I assembly and stability in muscle was not
possible due to insufﬁcient patient samples. However, cultured
skin ﬁbroblasts were available from Patients 3, 5, 19, 22 and
27. As cell lines do not consistently exhibit the complex I deﬁ-
cient phenotype (Mazzella et al., 1997; Benit et al., 2001;
Antonicka et al., 2003), the activity of the complex was ﬁrst as-
sessed in these ﬁbroblasts. In-gel complex I activity assays were
performed on protein samples separated on 1D blue-native PAGE.
Decreased complex I activity was identiﬁed in cell lines from
Patients 3, 5 and 27, and to a lesser extent in cells from Patient
22 (Fig. 4A). Fibroblasts of Patient 19 demonstrated complex I
activity comparable to controls.
Transcription of mutant and wild-type
NDUFS2 alleles
To ensure that all NDUFS2 alleles (both wild-type and mutant)
were being transcribed, total RNA was extracted from ﬁbroblasts
of Patients 3, 19, 22 and 27. Following DNase1 treatment and
Figure 4 Complex I in-gel activity and assembly in patient
ﬁbroblasts. (A) Complex I in-gel activity. Mitochondria-enriched
protein fractions (75mg) extracted from patient (P) and control
(C) ﬁbroblasts were separated on 5–13% 1D blue-native PAGE
gels. Gels were histochemically stained for 2h with 2mM
Tris–HCl (pH 7.4), 0.1mg/ml NADH and 2.5mg/ml nitrotetra-
zolium blue to assess complex I activity. (B) Complex I assembly.
Mitochondria-enriched protein fractions (75mg) extracted from
patient and control ﬁbroblasts were separated on 5–13% 1D
blue-native PAGE gels. Proteins were transferred to a polyviny-
lidine ﬂuoride membrane and probed with antibodies raised
against complex I NDUFS3 and complex II 70kDa subunits.
(C) Complex I subunit expression. Total cellular protein lysates
(10mg) of patient and control ﬁbroblasts were separated on
10% sodium dodecyl sulphate–PAGE gels then transferred to a
polyvinylidine ﬂuoride membrane. Western blotting was
performed with antibodies raised against complex I subunits
NDUFS9, NDUFS3 and NDUFB8, complex II 70kDa subunit
and b-actin.
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encompassing the putative pathogenic NDUFS2 mutations were
sequenced. In all cases, both NDUFS2 alleles were found to be
expressed (data not shown).
Assembly of complex I
Complex I assembly in patient and control ﬁbroblasts was assessed
by western analysis of a 1D blue-native PAGE gel (Fig. 4B). An
antibody against NDUFS3 was used to visualize complex I. To
conﬁrm loading, an antibody against the 70kDa subunit of com-
plex II was used. No complex I was detected in ﬁbroblasts of
Patient 3. Fully assembled complex I was present in ﬁbroblasts
of Patient 19 at levels comparable to controls. Intact complex I
was also observed in ﬁbroblasts of Patients 22 and 27, albeit at
noticeably lower levels than controls. Whilst a marked decrease in
fully assembled complex I was evident in ﬁbroblasts of Patient 5,
high levels of a lower molecular weight sub-complex were also
observed.
Complex I subunit protein expression
Protein expression levels of complex I subunits NDUFA9, NDUFS3
and NDUFB8 were assessed by sodium dodecyl sulphate–PAGE in
patient and control ﬁbroblasts (Fig. 4C). To check loading, the
expression levels of the 70kDa subunit of complex II and
b-actin were also analysed. No difference in NDUFS3 protein
levels was observed in patient cells relative to controls. NDUFA9
and NDUFB8 protein levels were reduced in ﬁbroblasts of Patients
3, 22 and 27 when compared with controls. No marked changes
in NDUFA9 protein levels were evident in ﬁbroblasts of Patient 5,
whereas NDUFB8 levels were slightly increased. In ﬁbroblasts of
Patient 19, the expression levels of both NDUFA9 and NDUFB8
subunits were strongly increased relative to controls.
Reactive oxygen species levels
Three control ﬁbroblasts [healthy neonatal (C1), paediatric (C2) or
MRC-5 embryonic lung ﬁbroblasts (C3)] demonstrated consistent
values of MitoSOX and nonyl acridine orange staining, which were
used as standards for cells without any mitochondrial defect. Cells
from Patients 3, 5, 19 and 22 did not show any elevated levels of
mitochondrial superoxides, while Patient 27 ﬁbroblasts displayed
an approximate 2.5-fold increase in MitoSOX staining (Bonferroni
corrected P50.05; Fig. 5). Analysis of mitochondrial mass revealed
no signiﬁcant differences in patient ﬁbroblasts when compared
with controls, although nonyl acridine orange staining of ﬁbro-
blasts of Patient 27 was slightly elevated.
Discussion
We report on the sequencing of functionally important
nuclear-encoded complex I genes in a clinically heterogeneous
cohort of 34 paediatric patients with isolated complex I deﬁciency
in skeletal muscle. Our investigations identiﬁed the previously re-
ported NDUFS8 mutation (c.236C4T, p.P79L) (Loeffen et al.,
1998a) in a homozygous state in an Asian patient with
Leigh-like syndrome as well as seven novel, potentially pathogenic
mutations in ﬁve additional patients, namely one homozygous
NDUFS1 change (c.1222C4T, p.R408C) in an Asian Leigh
syndrome patient from a consanguineous family and six com-
pound heterozygous NDUFS2 substitutions in four unrelated
white Caucasian infants with Leigh or Leigh-like syndrome
(c.353G4A and c.875T4C, c.875T4C and c.1328T4A, c.442G4A
and c.875T4C, and c.413G4A and c.998G4A). Interestingly, the
NDUFS2 c.875T4C (p.M292T) mutation was found in four
unrelated patients identiﬁed at two different diagnostic centres.
Until now, NDUFS2 mutations have been speciﬁcally associated
with encephalopathy and hypertrophic cardiomyopathy (Loeffen
et al., 2001). We demonstrate in this report, however, that com-
pound heterozygous NDUFS2 mutations can also occur in cases of
Leigh and Leigh-like syndromes. Several lines of evidence support
the pathogenicity of the novel NDUFS2 substitutions described:
the conservation of the affected amino acids across different spe-
cies, the absence of the sequence variants in 380 control alleles
and the independent inheritance of each individual sequence vari-
ant all strongly indicate that these mutations are responsible for
the isolated complex I deﬁciency observed. The complex I assem-
bly data are also indicative of NDUFS2 disruptions in these pa-
tients. NDUFS2 is located in the hydrophilic arm of complex I,
close to the membrane domain (Guenebaut et al., 1997), and
forms part of an early peripheral arm subassembly with subunits
NDUFS3, NDUFS7 and NDUFS8 (Ugalde et al., 2004b). Previous
blue-native PAGE studies have demonstrated that mutations
within these subunits result in markedly reduced levels of fully
assembled complex I (Procaccio and Wallace, 2004; Ugalde
et al., 2004a; Lebon et al., 2007). In keeping with these ﬁndings,
we observed reductions in full-size complex I levels in patient
ﬁbroblasts that exhibited a complex I deﬁciency. Moreover, we
demonstrated by western analysis that expression levels of sub-
units NDUFA9 and NDUFB8, known to integrate later in the
Figure 5 Reactive oxygen species levels and mitochondrial
mass in patient ﬁbroblasts. Mitochondrial superoxide levels were
determined using MitoSOX (white bars) and mitochondrial mass
was assessed with nonyl acridine orange (black bars) in ﬁbro-
blasts of Patients 3, 5, 19, 22 and 27. Values are mean and
standard error from at least three independent experiments.
a.U.=arbitrary units; C1=Control 1 (human neonatal skin
ﬁbroblasts); C2=Control 2 (healthy paediatric skin ﬁbroblasts);
C3=Control 3 (MRC-5 lung ﬁbrobasts); NAO=nonyl acridine
orange; *Bonferroni corrected P50.05.
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Vogel et al., 2007), were decreased relative to controls in these
cells. These data suggest NDUFA9 and NDUFB8 are more rapidly
degraded in the complex I-deﬁcient cell lines, possibly as a con-
sequence of not being maintained within a stable, fully assembled
enzyme complex. Invariant NDUFS3 protein levels indicate mutant
NDUFS2 can thus support the assembly of only an early peripheral
arm sub-complex. In the case of Patient 19, whose ﬁbroblasts
were not complex I deﬁcient, the increased levels of NDUFA9
and NDUFB8 may reﬂect a compensatory mechanism the cells
have acquired to overcome the NDUFS2 mutations.
Due to the large number of constitutive complex I subunits and
associated assembly factors, the vast majority of mutations asso-
ciated with isolated complex I deﬁciency that have been reported
to date are unique. Several recurrent mtDNA mutations have been
identiﬁed (Chol et al., 2003; Lebon et al., 2003; Sarzi et al., 2007)
and recently, Berger et al. (2008) uncovered an NDUFA11 intronic
splice site mutation in three unrelated consanguineous families. For
the ﬁrst time, we have identiﬁed multiple occurrences of nuclear
coding sequence mutations in NDUFS8 and in NDUFS2. The
NDUFS2 mutation (p.M292T) was associated with Leigh and
Leigh-like syndromes in four unrelated Caucasian families.
Microsatellite and SNP data suggest this transition is associated
with a particular chromosome 1 haplotype (spanning  1Mb
around NDUFS2), indicative of an ancient common founder for
this mutation within the European population, a notion that is
further corroborated by the diverse mtDNA haplogroups of
these patients. Prediction of the structural and functional effects
of this common NDUFS2 sequence variant (c.875T4C) using
PredictProtein (http://www.predictprotein.org) (Rost et al.,
2004) identiﬁed that an amino acid change from methionine to
threonine at residue 292 may result in the introduction of a pro-
tein kinase C phosphorylation site (Toll-like receptor) at position
p.292. NDUFS2 already contains a conserved protein kinase C
phosphorylation site (soluble leptin receptor) at the C-terminus
of the protein (Loeffen et al., 1998b); the introduction of an add-
itional site may affect the regulatory function of the protein, but
this has yet to be evaluated.
NDUFS1, along with NDUFS4, NDUFS6 and NDUFV1, is
located at the tip of the hydrophilic arm of complex I and, in
contrast with NDUFS2, incorporates much later in the complex I
assembly sequence. Consequently, mutations within these sub-
units are characterized by an accumulation of a  830kDa enzy-
matically inactive sub-complex intermediate (Ugalde et al., 2004a;
Iuso et al., 2006). Sub-complex accumulation in ﬁbroblasts
of Patient 5 is therefore indicative of a mutation in a
late-incorporating complex I subunit such as NDUFS1, as are the
protein expression data, which demonstrate no change in NDUFS3
or NDUFA9 levels, two subunits thought to assemble into complex
I before and at the same time, respectively, as NDUFS1 (Lazarou
et al., 2007; Vogel et al., 2007). Absence of the c.1222C4T tran-
sition in 60 healthy ethnically matched controls further corrobor-
ates the pathogenicity of the mutation, as does its presence in
both alleles of an affected sibling, whilst both unaffected parents
are heterozygous. In addition, the transition is likely to cause the
substitution of a conserved positively charged arginine residue to
an uncharged, sulphur-containing cysteine amino acid, the
structural consequences of which could include aberrant disulphide
bond formation, altered binding or disrupted iron–sulphur cluster
coordination.
Reported effects of complex I deﬁciency on levels of reactive
oxygen species production in patient ﬁbroblasts are contradictory.
Increases in reactive oxygen species production have been demon-
strated in patient ﬁbroblasts harbouring mutations in various com-
plex I subunits including NDUFS1, NDUFS2, NDUFS4 and
NDUFV1 (Iuso et al., 2006; Verkaart et al., 2007); however,
these same reports and others also describe no changes in intra-
cellular reactive oxygen species levels in cells with NDUFS4,
NDUFA1 or NDUFV1 mutations (Iuso et al., 2006; Verkaart
et al., 2007; Moran et al., 2010). In accordance with these con-
ﬂicting data, we found an increased level of oxidative stress in
only one of the patient cell lines (Patient 27; NDUFS2, p.R138Q
and p.R333Q). While the elevated reactive oxygen species levels
in these cells most likely reﬂect increased mitochondrial prolifer-
ation rather than increased reactive oxygen species production per
mitochondrion (Fig. 5), our results and others suggest different
mechanisms of disease pathogenesis, even for defects within the
same structural subunit of complex I. The speciﬁc location of a
mutation within a given subunit is seemingly important in inﬂuen-
cing reactive oxygen species production; however, further investi-
gations are still necessary to uncover the exact pathophysiological
mechanisms of reactive oxygen species production in complex I
deﬁcient cells.
In our cohort of 34 patients with isolated complex I deﬁciency,
we identiﬁed a nuclear genetic aetiology in 17.5% of cases, com-
parable to other nuclear gene sequencing studies in which the
frequency of genetically diagnosed patients ranged from 7.7%
to 25% (Bugiani et al., 2004; Ugalde et al., 2004a; Martin
et al., 2005). Similarly, Benit et al. (2004) identiﬁed a nuclear
genetic defect in 17% of their complex I deﬁcient patients using
denaturing high-performance liquid chromatography. Despite
more widespread nuclear gene screening, it is estimated that
underlying genetic defects (either mitochondrial or nuclear) are
still identiﬁed in only 50% of all complex I-deﬁcient cases
(Thorburn et al., 2004). This low frequency is undoubtedly due
to the fact that only a handful of the structural subunits and as-
sembly factors of complex I are analysed in each study. In order to
improve mutation ‘hit rates’, diagnostic strategies need to routine-
ly include screening of all complex I-associated genes. It is there-
fore imperative that more high-throughput and rapid approaches
be adopted, such as next generation sequencing, tiling arrays or
Surveyor
TM nuclease technology, which utilizes a celery endo-
nuclease highly speciﬁc for DNA mismatches that may be created
following hybridization of patient and wild-type DNA
(Pagniez-Mammeri et al., 2009). Concerted efforts to further
our understanding of complex I assembly and uncover all factors
implicated in this process are also necessary. Of note is the recent
approach taken by Pagliarini et al. (2008) to elucidate complex I
function, which relied on the phylogenetic proﬁling of MitoCarta,
a comprehensive compendium of the mitochondrial proteome.
These evolutionary analyses unearthed several strong candidates
for involvement in complex I activity, of which three have subse-
quently been deﬁned as disease-causing genes, C8orf38 (Pagliarini
NDUFS2 mutations in Leigh syndrome Brain 2010: 133; 2952–2963 | 2961et al., 2008), C3orf60 (Saada et al., 2009) and C20orf7 (Sugiana
et al., 2008).
In summary, we report here on the genetic screening of a
cohort of 34 paediatric patients with isolated complex I deﬁciency.
A plethora of novel compound heterozygous NDUFS2 mutations
were uncovered, including the c.875T4C (p.M292T) transition
that was repeatedly identiﬁed in four unrelated white Caucasian
infants with Leigh or Leigh-like syndrome. Homozygous substitu-
tions in NDUFS1 (c.1222C4T, p.R408C) and NDUFS8 (c.236C4T,
p.P79L) were also discovered in two patients from unrelated con-
sanguineous families who presented with Leigh and Leigh-like
syndrome, respectively. Based on our results, we propose that
NDUFS2 is a mutation hotspot among white Caucasian patients
with isolated complex I deﬁciency and Leigh or Leigh-like syn-
drome and recommend routine screening of the gene for patients
with isolated complex I deﬁciency.
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